Fulgent Genetics
Total Raised
$29.42MDeal Terms
1Investments
4Funding, Valuation & Revenue
3 Fundings
Fulgent Genetics has raised $29.42M over 3 rounds.
Fulgent Genetics's latest funding round was a IPO for $37.8M on September 29, 2016.
Fulgent Genetics's latest post-money valuation is from September 2016.
Sign up for a free demo to see Fulgent Genetics's valuations in September 2016 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
9/29/2016 | IPO | $37.8M | 2 | |||
5/24/2016 | Unattributed - II | |||||
10/30/2015 | Unattributed |
Date | 9/29/2016 | 5/24/2016 | 10/30/2015 |
|---|---|---|---|
Round | IPO | Unattributed - II | Unattributed |
Amount | $37.8M | ||
Investors | |||
Valuation | |||
Revenue | |||
Sources | 2 |
Fulgent Genetics Deal Terms
1 Deal Term
Fulgent Genetics's deal structure is available for 1 funding round, including their IPO from September 29, 2016.
Round | IPO |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO |
Fulgent Genetics Acquisitions
5 Acquisitions
Fulgent Genetics acquired 5 companies. Their latest acquisition was Stratadx on December 22, 2025.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
12/22/2025 | Acquired - II | 3 | ||||
11/7/2022 | ||||||
4/18/2022 | ||||||
8/9/2021 | Debt | |||||
5/10/2021 | Other |
Date | 12/22/2025 | 11/7/2022 | 4/18/2022 | 8/9/2021 | 5/10/2021 |
|---|---|---|---|---|---|
Investment Stage | Debt | Other | |||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acquired - II | ||||
Sources | 3 |
Fulgent Genetics Investments
4 Investments
Fulgent Genetics has made 4 investments. Their latest investment was in Spatial Genomics as part of their Series A on February 23, 2022.
Fulgent Genetics Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
2/23/2022 | Series A | Spatial Genomics | $56M | Yes | 12 West Capital, and Undisclosed Investors | 6 |
9/22/2021 | Unattributed VC | |||||
7/1/2021 | Series B | |||||
1/1/2017 | Corporate Minority |
Date | 2/23/2022 | 9/22/2021 | 7/1/2021 | 1/1/2017 |
|---|---|---|---|---|
Round | Series A | Unattributed VC | Series B | Corporate Minority |
Company | Spatial Genomics | |||
Amount | $56M | |||
New? | Yes | |||
Co-Investors | 12 West Capital, and Undisclosed Investors | |||
Sources | 6 |
Compare Fulgent Genetics to Competitors
MedySapiens focuses on cognitive computing for healthcare, operating in the digital health and genomics sectors. The company integrates artificial intelligence and genomics to support healthcare providers, particularly in the diagnosis and treatment of rare diseases. It was founded in 2016 and is based in Seoul, South Korea.
Centogene is a company focused on providing data-driven solutions in the healthcare sector, specifically for rare and neurodegenerative diseases. The company offers diagnostic testing services, integrating multiomic technologies with their biodatabank to provide comprehensive clinical and biochemical information about each disease. This approach aids in the understanding and treatment of these diseases, primarily serving patients, physicians, and pharmaceutical companies. It was founded in 2006 and is based in Rostock, Germany.
Ambry Genetics focuses in clinical genomic diagnostics within the healthcare sector. The company provides genetic testing services, including hereditary cancer analysis and exome sequencing for rare diseases, to detect and classify deoxyribonucleic acid (DNA) variants. It was founded in 1999 and is based in Aliso Viejo, California. In November 2024, Ambry Genetics was acquired by Tempus.
GeneDx offers testing for rare Mendelian disorders, and gene panels for inherited cardiac disorders, inherited cancer syndromes, neurological disorders, and mitochondrial disorders. On January 18th, 2022, GeneDx was acquired by Sema4 at a valuation between $473M and $623M.
23andMe operates as a consumer genetics and research company specializing in DNA testing. It offers services including ancestry composition analysis, genetic health risk reports, carrier status reports, and pharmacogenetics information. 23andMe also provides services such as exome sequencing and biannual blood testing. It was founded in 2006 and is based in Sunnyvale, California.
Invitae operates as a genetic information company. It offers advanced genetic testing services providing genetic information for a variety of genetic disorders to improve patient care with actionable insights based on deoxyribonucleic acid (DNA). It was founded in 2010 and is based in San Francisco, California. In February 2024, Invitae filed for bankruptcy.
Loading...